Navigation Links
InspireMD Reports Financial Results for Quarter Ended September 30, 2013
Date:11/11/2013

or amortization expenses during the three months ended September 30, 2013. In contrast, during the three months ended September 30, 2012, we recognized approximately $4.0 million in non-recurring, non-cash cost associated with the Company's previously retired convertible debt and associated warrants. If the non-cash effects in the three months ended September 30, 2012, as well as the non-cash effects in the three months ended September 30, 2013 are removed, financial expenses for the three months ended September 30, 2012 would have totaled approximately $0.2 million, as compared to approximately $20,000 of financial income for the three months ended September 30, 2013.

The net loss for the quarter ended September 30, 2013 totaled $3.9 million, or $0.12 per basic and diluted share, a decrease of 47.4% compared to a net loss of $7.5 million, or $0.44 per basic and diluted share in the same period in 2012.

Non-GAAP net loss for the quarter ended September 20, 2013 was $3.0 million, or $0.09 per basic and diluted share, an increase of 15.7% compared to a non-GAAP net loss of $2.6 million or $0.15 for the same period in 2012.  The non-GAAP net loss for the quarter ended September 30, 2013 primarily excludes $0.9 million of share-based compensation. The non-GAAP net loss for quarter ended September 30, 2012 primarily excludes $4.0 million in non-recurring, non-cash cost associated with the Company's previously retired convertible debt and associated warrants and $1.0 million in share-based compensation.

Cash and Cash EquivalentsAt September 30, 2013, cash and cash equivalents were $11.4 million, a decrease of 22.8% compared to $14.8 million at June 30, 2013. The Company's cash decreased in line with its anticipated burn rate.

On October 24, 2013, the Company secured $10 million in venture debt financing to support product development and clinical expansion.

Change to Fiscal YearAs announced on September 17th, the Compan
'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Consolidated Net Profit increased by 43.65 % ... , India Business grew by 20.87% to Rs. 3,971.59 ... Mn Rest of World (ROW) Business grew by 20.67% ... 34.53% to Rs. 977.26 Mn Latin America Business grew ... Glenmark Pharmaceuticals Limited, the research-led global integrated pharmaceutical company, today announced ...
(Date:7/24/2014)... 24, 2014 /PRNewswire-iReach/ -- Delivery of the Report ... placed. Photo - http://photos.prnewswire.com/prnh/20140723/129707 ... in-depth market survey on Global and Chinese Hemodialysis ... information of Hemodialysis Machine including its classification, application ... and China,s top manufacturers of Hemodialysis Machine listing ...
(Date:7/24/2014)... 2014 Cancer patients in the west of ... treatment closer to home when a new radiotherapy center opens ... Systems (NYSE: VAR ) has been selected to ... June for four TrueBeam™ medical linear accelerators. ... efficient radiotherapy and radiosurgery treatments, will replace older treatment machines ...
Breaking Medicine Technology:Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 2Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 3Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 4Hemodialysis Machine Industry for Global and Chinese Markets Forecast to 2019 5Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 2Varian Medical Systems Selected to Equip First Satellite Radiotherapy Center in Scotland 3
... Mass., Dec. 8, 2010 Decision Resources, one ... for pharmaceutical and healthcare issues, finds that although ... of care for first- and second-line treatment of ... replace paclitaxel/carboplatin as the standard second-line treatment for ...
... 8, 2010 Sunridge International (OTC Bulletin Board: ... preparing to start the short term clinical trials needed ... L.L.C., Sunridge,s exclusive distributor for several Middle Eastern countries, ... to attend the start of their clinical trials.  Dr. ...
Cached Medicine Technology:For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients 2For the Treatment of Ovarian Cancer, Pegylated Liposomal Doxorubicin/Carboplatin Will Replace Paclitaxel/Carboplatin as the Standard Second-Line Treatment for Platinum Sensitive Patients 3
(Date:7/24/2014)... PHILADELPHIA For rats bearing human breast tumors, exposure ... to the breast cancer drug tamoxifen, according to data ... the American Association for Cancer Research. The negative effects ... by giving rats a melatonin supplement during the night. ... patients with hormone receptor-positive breast cancer," said Steven M. ...
(Date:7/24/2014)... Denver, CO (PRWEB) July 24, 2014 Ticket ... vs. AS Roma Tickets in Denver at the Sports Authority ... Champions Cup (or World Football Challenge) has brought some of the ... a mini-tournament. With the World Cup still being raved about weeks ... have the chance to see some of the biggest stars in ...
(Date:7/24/2014)... New York (PRWEB) July 24, 2014 ... lawsuits ( http://www.injurybeacon.com/granuflo-dialysis/lawsuit/ ) in the U.S. ... qualified protective order for plaintiff medical information covered ... Act. According to the July 16th Order, U.S. ... attorneys for Fresenius Medical Care the right ...
(Date:7/24/2014)... (ASAE) announced its 2014 Power of A Award winners, ... Anesthesiologists (ASA). , The ASA Global Humanitarian Outreach ... one of the top honors from ASAE. GHO was ... through education on the global anesthesia crisis and supporting ... was also honored with a Power of A Silver ...
(Date:7/24/2014)... 24, 2014 Pools and beaches are the ... can be dangerous, especially for small children, so Amica ... , According to the Centers for Disease Control and Prevention, ... at risk for water-related injuries and deaths. It’s important to ... water, so Amica is offering the following tips from the ...
Breaking Medicine News(10 mins):Health News:Exposure to dim light at night may make breast cancers resistant to tamoxifen 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 2Health News:Manchester United vs. AS Roma Tickets Denver Sports Authority Field at Mile High: Ticket Down Cuts Ticket Prices for Guinness International Champions Cup Match 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Keep Kids Safe in the Water with 5 Tips from Amica 2
... Oct. 9 Actor Joe Pantoliano,reveals a personal ... mother,struggled with untreated bipolar disorder, in a guest ... National Alliance on Mental,Illness (NAMI)., Pantoliano,s entry ... a few days before the opening of his ...
... shows , TUESDAY, Oct. 9 (HealthDay News) -- U.S. ... to a treatment for the hereditary, progressive neurological disorder ... molecule called C2-8 appears to reduce HD-related neurological damage ... team from the MassGeneral Institute for Neurological Disorders (MIND), ...
... heart attack risk, study finds , , TUESDAY, Oct. 9 (HealthDay ... who has had a heart attack will have another major ... shown that workplace stress boosts heart woes, but this is ... and other major events, the report,s authors said. , The ...
... Johns Hopkins scientists have developed a potentially novel way ... potent barrages of radiation inside cancer cells, unlike current ... attack from the outside and cause unwanted side effects. ... cells, the new radiation delivery system proved able to ...
... The March of,Dimes congratulates Mario R. Capecchi, Ph.D., ... D.Phil., FRS, former recipients of the,March of Dimes Prize ... Physiology or Medicine. The Nobel Committee announced yesterday ... principles for introducing specific gene,modifications in mice by the ...
... Health plans are expecting premium,rate increases in 2008 ... of 8.2%. This is the fourth consecutive decline in ... survey in September of 2007. The survey,contained 76 responses, ... Separately, the survey notes that the East South Central ...
Cached Medicine News:Health News:Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side 2Health News:Molecule Promising Against Huntington's Disease 2Health News:Stressful Jobs Hard on the Heart 2Health News:Stressful Jobs Hard on the Heart 3Health News:Inside job: new radioactive agents for colon cancer work inside cells 2Health News:Nobel Honors 3 Former March of Dimes Prize Recipients 2
... mini-cells has always distinguished itself by ... tradition continues with the patented XCell ... gel tension wedge in place of ... models makes the XCell SureLock and ...
... Multidizer is designed with a variety of ... - all in one unit. Shake, rock, ... operating compartments allow for hybridization and blotting ... , The upper chamber uses a ...
... unit ideal for use in laboratories with low ... set at 12 rpm , Temperature control ... capacity of four 35 x 150mm bottles, eight ... , Consistent, repeatable results achieved with microprocessor ...
Maxi XL Hybridization Oven for Extra Large bottles. 6 bottle (70 mm) rotisserie + shaker tray available for simultaneous use. Includes linear and orbital shaker trays, 4 extra large bottles, pack o...
Medicine Products: